Evidence map›Paper›PMID 29524031›Full record

Trial reportMedical oncology (Northwood, London, England)2018

Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma.

Ryoma Igarashi, Takamitsu Inoue, Nobuhiro Fujiyama, Norihiko Tsuchiya, Kazuyuki Numakura, Hideaki Kagaya, Mitsuru Saito, Shintaro Narita, Shigeru Satoh, Takenori Niioka and 2 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Medical oncology (Northwood, London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Genomic Alterations of Renal Cell Carcinoma and Clinical Implications in the Chinese Population.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Ryoma IgarashiDepartment of Urology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.
Takamitsu InoueDepartment of Urology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan. takamitu@doc.med.akita-u.ac.jp.
Nobuhiro FujiyamaCenter for Kidney Disease and Transplantation, Akita University Hospital, Akita, Japan.
Norihiko TsuchiyaDepartment of Urology, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Kazuyuki NumakuraDepartment of Urology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.
Hideaki KagayaDepartment of Pharmacy, Akita University Hospital, Akita, Japan.
Mitsuru SaitoDepartment of Urology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.
Shintaro NaritaDepartment of Urology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.
Shigeru SatohCenter for Kidney Disease and Transplantation, Akita University Hospital, Akita, Japan.
Takenori NiiokaDepartment of Pharmacy, Akita University Hospital, Akita, Japan.
Masatomo MiuraDepartment of Pharmacy, Akita University Hospital, Akita, Japan.
Tomonori HabuchiDepartment of Urology, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan.
Akita University · JPAkita University Hospital · JPJapan Agency for Medical Research and Development · JPHirosaki University Hospital · JPYamagata University · JP

Funding

the Japanese Society for the Promotion of Science 16H02679the Japanese Society for the Promotion of Science 23590168the Japanese Society for the Promotion of Science 25293332
6 · The paper itself

Abstract

Axitinib is a potent second-line molecular-targeted agent for metastatic renal cell carcinoma (mRCC). Axitinib pharmacokinetics and its relation with genetic polymorphisms were evaluated to predict the adverse events (AEs) and efficacy of axitinib. We analyzed 46 patients with mRCC who were treated with axitinib. The plasma axitinib level was measured at 0, 2, 4, 8, and 12 h after administration (C

Indexed as

AdultAgedAged, 80 and overAntineoplastic AgentsAxitinibCarcinoma, Renal CellFemaleGenotypeGlucuronosyltransferaseHumansImidazolesIndazolesKidney NeoplasmsMaleMiddle AgedPolymorphism, Single NucleotideAntineoplastic AgentsAxitinibGlucuronosyltransferaseImidazolesIndazolesProtein Kinase InhibitorsUGT1A1 EnzymeGenetic polymorphismsMolecular-targeted agentsRenal cell carcinomaTherapeutic drug monitoring

Identifiers

PMID29524031
OpenAlexW2793940188

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.